Abstract
The pathology of Alzheimer's disease (AD) features amyloid beta peptide deposition, intracellular neurofibrillary tangles and deficits in the cholinergic pathway. Abnormal blood pressure is recognised as a risk factor for the development of AD, although the underlying mechanisms remain unproven. This review proposes angiotensins and associated enzymatic pathways as important mediators of recognised but undefined links between blood pressure and AD. Evidence in support of this involvement translates consistently from the most basic in vitro, in vivo and ex vivo experimental paradigms to more complex human-based observational and experimental studies, which also fortunately offer potential for therapeutic interventions against AD.
| Translated title of the contribution | Angiotensins and Alzheimer's disease: a bench to bedside overview |
|---|---|
| Original language | English |
| Pages (from-to) | 3 |
| Number of pages | 1 |
| Journal | Alzheimer's Research and Therapy |
| Volume | 1 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - Jul 2009 |
Research Groups and Themes
- Translational Dementia Research Group
